Mind Medicine (MindMed) Inc.DFTX決算レポート
Nasdaq · biotechnology industry
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Commodore | 9.90% | 8.2M | ▲ +1.60pp | 2024-11-14 |
| Deep Track Capital, LP | 9.49% | 6.7M | — | 2024-03-15 |
| BlackRock, Inc. | 7.00% | 5.7M | 変動なし | 2024-11-08 |
インサイダー取引
Net 90d: −$797.0K · buys $0 / sells $797.0K期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-03-25 | Mark Sullivan | Chief Legal Officer | Sell (open market) | 10.7K | $18.47 | $197.7K |
| 2026-03-25 | Robert Barrow | Chief Executive Officer | Sell (open market) | 24.4K | $18.47 | $451.2K |
| 2026-03-25 | Daniel Karlin | Chief Medical Officer | Sell (open market) | 8.0K | $18.47 | $148.1K |
| 2026-02-03 | Wiley Matthew T. | Chief Commercial Officer | Grant | 115.0K | $0.00 | $0 |
| 2026-02-03 | Brandi Roberts | Chief Financial Officer | Grant | 150.0K | $0.00 | $0 |
| 2026-02-03 | Mark Sullivan | Chief Legal Officer | Grant | 125.0K | $0.00 | $0 |
| 2026-02-03 | Daniel Karlin | Chief Medical Officer | Grant | 150.0K | $0.00 | $0 |
| 2026-02-03 | Robert Barrow | Chief Executive Officer | Grant | 320.0K | $0.00 | $0 |
1–8 of 8